Gram-positive bacteremia and Gram-negative bacteremia
Conditions
Interventions
1) Control Clinical management with conventional microbiological identification methods
2) Intervention Clinical management with conventional microbiological identification methods and Verigene sys
Sponsors
Tsukuba Medical Center Hospital
Miroku Medical Laboratory Inc.
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Gram positive bacteremia or Gram negative bacteremia detected by BacT/Alert 3D system (Sysmex bioMerieux Co., Ltd, Tokyo, Japan)
Exclusion criteria
Exclusion criteria: 1)If only one set of blood cultures is positive among two sets of blood cultures incubated, and Staphylococcus spp. or Gram-positive rods are suspected by Gram stain examination. 2)If one set of blood culture is positive with Staphylococcus spp. suspected by Gram stain examination and contamination is clinically considered. 3)If blood cultures are positive and Gram-positive rods are suspected in nosocomial bacteremia patients. 4)If differentiation between Gram-positive and Gram-negative bacteria is difficult by Gram stain examination. 5)If more than two species of bacteria are suspected by Gram stain examination. 6)If more than 24 hours have passed after positive blood culture alarm by BacT/Alert 3D system. 7)If Gram stain examination of positive blood culture indicates the same bacteria as previous positive blood culture obtained within the past week. 8)If patients have already been referred or transferred to other hospitals. 9)If patients are not hospitalized in Tsukuba Medical Center Hospital. 10)If palliative care is performed without treatment for infections. 11)If patients have already died at the time of reporting the results of Gram staining.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Duration before the initiation of appropriate antimicrobial therapy after obtaining blood cultures. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1)Additional cost requirement of antimicrobial agents compared with appropriate antimicrobial therapy 2)14 days mortality 3)30 days mortality | — |
Countries
Japan
Contacts
Public ContactHiromichi Suzuki
Tsukuba Medical Center Hospital Division of Infectious Diseases, Department of Medicine/Department of Clinical Laboratory Medicine
Outcome results
None listed